Business
The Jenex Corporation Announces AGM Results and Submits Application to Graduate to TSXV
Toronto, Ontario--(Newsfile Corp. - November 23, 2017) - The Jenex Corporation (TSXV: JEN.H)...
About this update from Therma Bright Inc.
[{"type":"text","content":"The Jenex Corporation Announces AGM Results and Submits Application to Graduate to TSXVToronto, Ontario--(Newsfile Corp. - November 23, 2017) - The Jenex Corporation (TSXV: JEN.H) (\"Jenex\" or the \"Company\"), a progressive medical device technology company, would like to announce the voting results from its Annual General and Special Meeting of shareholders (the \"Meeting\") held last week in Toronto, Ontario on November 15, 2017. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 10,439,138, representing 41.26% of the Company's issued and outstanding common shares.All of the matters put forward before shareholders for consideration and approval, as set out in the Company's Management Information Circular dated October 11, 2017, were approved by the requisite majority of votes cast at the Meeting, which matters included, among other things: (i) the re-election of Rob Fia, John Gamble and Joseph Heng as directors of the Company for the next year; (ii) the approval of the issuance of shares to insiders pursuant to debt settlements; and (iii) the approval of the creation of a new Control Person (as such term is defined in the policies of the TSX Venture Exchange (\"TSXV\")). The Company has now submitted the results of the Meeting to the TSXV in support of its application to graduate to Tier 2 on the TSXV. The Company will provide shareholders with an update on the status of this graduation application in due course. Jenex would like to report that results from the Zika Virus tests with our patent pending TherOZap™ technology are expected to be announced in the short term and prior to year-end. The Company will report results and further data as it becomes available.About Jenex:Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of t...